Announcement of TTY Biopharm's unaudited income information in May 2025
2025.6.9
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2025/06/09 | Time of announcement | 16:46:57 |
| Subject | Announcement of TTY Biopharm's unaudited income information in May 2025 | ||||
| Date of events | 2025/06/09 | To which item it meets | paragraph 53 | ||
| Statement | 1.Date of occurrence of the event:2025/06/09 2.Company name:TTY Biopharm Co., Ltd. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:N/A 5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of $537,710 thousands (expressed in NT dollars; unaudited), a consolidated operating profit of $159,729 thousands, and a consolidated income before tax of $118,204 thousands in May 2025; net income attributed to stockholders of the company was $78,253 thousands; EPS is $0.31. Year-to-date consolidated net sales was $2,435,972 thousands (in NTdollars; unaudited), a consolidated operating profit was $666,520 thousands, and consolidated income before tax was $733,620 thousands until May 2025; year-to-date net income attributed to stockholders of the company was $543,954 thousands; EPS is $2.19. 6.Countermeasures:None. 7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The numbers above are unaudited. In term of the final net sales and profits, quarterly financial reports audited by independent accountants will prevail. |
||||